Automotive Cyber Security Market to Reach US$ 1,150.6 Mn by 2026 – Persistence Market Research
/
Date06 Apr 2018
New York, April 06, 2018 (GLOBE NEWSWIRE) — Rapidly increasing adoption of connected car technology by automakers across the world is recognized to be a... Read More →
IES Holdings Acquires Azimuth Communications
/
Date06 Apr 2018
HOUSTON, April 06, 2018 (GLOBE NEWSWIRE) — IES Holdings, Inc. (or “IES”) (NASDAQ:IESC) today announced that its subsidiary IES Communications has acquired Azimuth Communications, Inc.... Read More →
NW Natural Announces Dividend
/
Date06 Apr 2018
PORTLAND, Ore., April 05, 2018 (GLOBE NEWSWIRE) — The Board of Directors of Northwest Natural Gas Company (NYSE:NWN), dba NW Natural, has declared a quarterly... Read More →
Jyske Bank publishes offer document
/
Date06 Apr 2018
In the Corporate Announcement of 13 March 2018, Jyske Bank stated that it had decided to make a voluntary offer to acquire all outstanding shares... Read More →
Westwood Holdings Group, Inc. to Host First Quarter 2018 Conference Call/Webcast
/
Date06 Apr 2018
DALLAS, April 05, 2018 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. (NYSE:WHG) will release its first quarter 2018 earnings after the close of the New York Stock... Read More →
BioCorRx Provides Business Update for the Full Year Ended 2017
/
Date06 Apr 2018
ANAHEIM, CA, April 06, 2018 (GLOBE NEWSWIRE) — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid... Read More →
Aclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada
/
Date06 Apr 2018
The agreement will expand the availability of the first and only U.S. FDA-approved prescription product for the treatment of raised seborrheic keratoses (SKs) WAYNE, Pa.,... Read More →
Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle Genetics
/
Date06 Apr 2018
CAMBRIDGE, Mass., April 03, 2018 (GLOBE NEWSWIRE) — Unum Therapeutics Inc. (“Unum Therapeutics”) (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy... Read More →